Assessment of Interleukin-6 and Hepcidin in the Therapeutic Follow-up of Inflammatory Anaemia in Multidrug-resistant Tuberculosis and Haemodialysis Patients in Abidjan, Ivory Coast
Bahi Gnogbo Alexis *
Department of Medical and Fundamental Biochemistry, Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire and Department of Biology and Health, Félix Houphouët Boigny University, Abidjan, Côte d'Ivoire.
Boyvin Lydie
Department of Medical and Fundamental Biochemistry, Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire.
Dagnogo Oléfongo
Department of Biology and Health, Félix Houphouët Boigny University, Abidjan, Côte d'Ivoire.
Yao Ahou Catherine
Department of Bacteriology and Virology, Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire.
Ehouman Octave
Department of Bacteriology and Virology, Treichville University Hospital, Abidjan, Côte d'Ivoire.
Yayé Yapi Guillaume
Department of Biochemistry and Microbiology, University of Jean Lorougnon Guédé, Daloa, Côte d'Ivoire.
Djaman Allico. Joseph
Department of Medical and Fundamental Biochemistry, Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire and Department of Biology and Health, Félix Houphouët Boigny University, Abidjan, Côte d'Ivoire.
*Author to whom correspondence should be addressed.
Abstract
Background: Inflammatory anaemia complicates multidrug-resistant tuberculosis (MDR-TB) and chronic renal failure (CRF), and altered iron availability may contribute to persistent anaemia despite iron supplementation or erythropoietin therapy.
Aim: This study evaluated interleukin-6 (IL-6), hepcidin and ultrasensitive C-reactive protein (CRPus) as biochemical markers relevant to therapeutic follow-up in these conditions.
Methods: A prospective experimental study included 30 MDR-TB patients receiving treatment and iron supplementation, 30 haemodialysis patients with chronic kidney disease receiving recombinant erythropoietin, and 30 controls. CRPus was measured by latex-enhanced immunoturbidimetry, while IL-6 and hepcidin were quantified by enzyme-linked immunosorbent assay. Principal component analysis, the Kruskal–Wallis test and Dunn’s post-hoc comparisons were used for statistical analysis.
Results: Mean IL-6 concentrations were 107.70 ± 43.68 pg/mL in MDR-TB patients, 132.70 ± 113.90 pg/mL in CRF patients and 3.36 ± 0.92 pg/mL in controls. CRPus was highest in MDR-TB patients (41.90 ± 45.19 mg/L), compared with CRF patients (5.95 ± 6.31 mg/L) and controls (3.65 ± 3.14 mg/L). Hepcidin concentrations were similar in MDR-TB and CRF patients (41.24 ± 3.02 and 40.82 ± 3.10 µg/L, respectively) and higher than in controls (22.97 ± 3.69 µg/L).
Conclusion: The findings indicate distinct inflammatory biomarker profiles in MDR-TB and CRF. IL-6 and hepcidin may be useful candidates for further evaluation in monitoring inflammatory anaemia.
Keywords: Interleukin-6, hepcidin, multidrug-resistant tuberculosis, haemodialysis patients, Côte d’Ivoire